Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis

Cancer Science

Volumn 105, Issue 9, 2014, Pages 1100-1108

  Hamabe, Atsushi ^a   Yamamoto, Hirofumi ^a   Konno, Masamitsu ^a   Uemura, Mamoru ^a   Nishimura, Junichi ^a   Hata, Taishi ^a   Takemasa, Ichiro ^a   Mizushima, Tsunekazu ^a   Nishida, Naohiro ^a   Kawamoto, Koichi ^a   Koseki, Jun ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   Ishii, Hideshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Hexokinase; Invasion; Metastasis; Pyruvate dehydrogenase

Indexed keywords

HEXOKINASE 2; PHOSPHOTRANSFERASE; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE E1 ALPHA; UNCLASSIFIED DRUG; HEXOKINASE; PHOSPHOPROTEIN; PYRUVATE DEHYDROGENASE E1ALPHA SUBUNIT;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER METABOLISM; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CANCER CELL LINE; COLORECTAL TUMOR; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; ADENOCARCINOMA; AGED; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ENZYMOLOGY; INTESTINE MUCOSA; INVASION; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE; TUMOR INVASION; TUMOR RECURRENCE;

COLORECTAL CANCER; HEXOKINASE; INVASION; METASTASIS; PYRUVATE DEHYDROGENASE;

ADENOCARCINOMA; AGED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEXOKINASE; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRUVATE DEHYDROGENASE (LIPOAMIDE);

EID: 84910016810     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12487     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Vaiopoulos AG, Athanasoula KC, Papavassiliou AG. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta 2014; 1842: 971-80.
3. Ribelles N, Santonja A, Pajares B, Llacer C, Alba E. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev 2014; 40: 293-9.
4. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-4.
5. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-82.
6. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
7. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3.
8. Yi W, Clark PM, Mason DE et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012; 337: 975-80.
9. Patra KC, Wang Q, Bhaskar PT et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-28.
10. Fan J, Shan C, Kang HB et al. Tyr Phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell 2014; 20: 534-48.
11. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006; 25: 4683-96.
12. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003; 206: 2049-57.
13. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-12.
14. Kolobova E, Tuganova A, Boulatnikov I, Popov KM. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J 2001; 358: 69-77.
15. Roche TE, Baker JC, Yan X et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol 2001; 70: 33-75.
16. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci 2013; 104: 275-81.
17. Kaplon J, Zheng L, Meissl K et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013; 498: 109-12.
18. Lyshchik A, Higashi T, Hara T et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest 2007; 25: 154-62.
19. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer 2012; 106: 1713-7.
20. Ueno H, Hase K, Hashiguchi Y et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. J Gastroenterol 2013; Epub ahead of print.
21. Ueno H, Mochizuki H, Hashiguchi Y et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-94.
22. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40: 127-32.
23. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-502.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
25. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 2006; 66: 9583-90.
26. Yokobori T, Iinuma H, Shimamura T et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013; 73: 2059-69.
27. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273: F563-74.
28. Strutz F, Zeisberg M, Ziyadeh FN et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002; 61: 1714-28.
29. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
30. Singleterry J, Sreedhar A, Zhao Y. Components of cancer metabolism and therapeutic interventions. Mitochondrion 2014; 6: 50-55.
31. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70: 5649-69.
32. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8.
33. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
34. Oshiro R, Yamamoto H, Takahashi H et al. C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Cancer Sci 2012; 103: 1155-64.
35. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013; 108: 2088-96.
36. LA Zlobec I. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-61.
37. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516.
38. Watanabe T, Itabashi M, Shimada Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012; 17: 1-29.
39. Galamb O, Spisak S, Sipos F et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer 2010; 102: 765-73.
40. Lin G, He X, Ji H, Shi L, Davis RW, Zhong S. Reproducibility probability score-incorporating measurement variability across laboratories for gene selection. Nat Biotechnol 2006; 24: 1476-7.
41. Skrzypczak M, Goryca K, Rubel T et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE 2010; 5: e13091.
42. Smith JJ, Deane NG, Wu F et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138: 958-68.
43. Staub E, Groene J, Heinze M et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med 2009; 87: 633-44.
44. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009; 92: 329-33.
45. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 2008; 118: 3835-7.
46. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010; 6: 127-48.
47. Hurd TR, DeGennaro M, Lehmann R. Redox regulation of cell migration and adhesion. Trends Cell Biol 2012; 22: 107-15.